Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin)

Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin).

There are several good reasons for the UK Department of Health to recommend the appraisal of bevacizumab for the treatment of eye conditions by the National Institute for Health and Clinical Excellence. These reasons will extend to other drugs when similar situations arise in the future.

Intravitreal Injection of Bevacizumab (Avastin) to Treat Posterior Capsule Neovascularization

We report a 64-year-old diabetic woman who developed neovascularization of the posterior capsule 2 years after cataract surgery and intraocular lens implantation. The patient was treated with single injection of 1.25 mg of intravitreal bevacizumab (Avastin) via pars plana. After one week, complete regression of the posterior capsule neovascularization was achieved allowing us to perform Nd: YAG...

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

PURPOSE To describe the pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits. METHODS The right eye of 20 rabbits was injected intravitreally with 1.25 mg/0.05 mL bevacizumab. Both eyes of four rabbits each time were enucleated at days 1, 3, 8, 15, and 29. Bevacizumab concentrations were measured in serum, aqueous humor, and vitreous. RESULTS Maximum vitreous (406.25 μg/mL) an...

Testing intravitreal toxicity of bevacizumab (Avastin).

PURPOSE To evaluate the retinal toxicity of varying doses of bevacizumab when injected intravitreally in rabbits. Bevacizumab has been approved by the US Food and Drug Administration for the treatment of metastatic colorectal cancer. MATERIALS AND METHODS Twelve New Zealand albino rabbits were used for this study and divided into four groups. Four concentrations of bevacizumab were prepared: ...

Using intravitreal bevacizumab (Avastin®) – Indian Scenario